0000899243-21-013283.txt : 20210324
0000899243-21-013283.hdr.sgml : 20210324
20210324160514
ACCESSION NUMBER: 0000899243-21-013283
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210322
FILED AS OF DATE: 20210324
DATE AS OF CHANGE: 20210324
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Pons Jaume
CENTRAL INDEX KEY: 0001816977
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39386
FILM NUMBER: 21768261
MAIL ADDRESS:
STREET 1: C/O ALX ONCOLOGY HOLDINGS INC.
STREET 2: 866 MALCOLM ROAD, SUITE 100
CITY: BURLINGAME
STATE: CA
ZIP: 94010
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ALX ONCOLOGY HOLDINGS INC
CENTRAL INDEX KEY: 0001810182
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 850642577
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 866 MALCOLM ROAD, SUITE 100
CITY: BURLINGAME
STATE: CA
ZIP: 94010
BUSINESS PHONE: 650-466-7125
MAIL ADDRESS:
STREET 1: 866 MALCOLM ROAD, SUITE 100
CITY: BURLINGAME
STATE: CA
ZIP: 94010
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-03-22
0
0001810182
ALX ONCOLOGY HOLDINGS INC
ALXO
0001816977
Pons Jaume
C/O ALX ONCOLOGY HOLDINGS INC.
866 MALCOLM ROAD, SUITE 100
BURLINGAME
CA
94010
1
1
0
0
President and CEO
Common Stock
2021-03-22
4
M
0
16700
1.91
A
568046
D
Common Stock
2021-03-22
4
S
0
1200
63.7875
D
566846
D
Common Stock
2021-03-22
4
S
0
900
64.9846
D
565946
D
Common Stock
2021-03-22
4
S
0
600
66.325
D
565346
D
Common Stock
2021-03-22
4
S
0
1500
67.1823
D
563846
D
Common Stock
2021-03-22
4
S
0
2700
68.27
D
561146
D
Common Stock
2021-03-22
4
S
0
9200
69.7671
D
551946
D
Common Stock
2021-03-22
4
S
0
600
70.1243
D
551346
D
Employee Stock Option (right to buy)
1.91
2021-03-22
4
M
0
16700
0.00
D
2029-09-12
Common Stock
16700
89019
D
The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 28, 2021.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.33 to $64.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (8) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.64 to $65.25, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.80 to $66.69, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.81 to $67.79, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.81 to $68.80, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.97 to $69.95, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.20, inclusive.
The option is subject to an early exercise provision and is immediately exercisable. Shares subject to the option vest in 48 equal monthly installments beginning on June 16, 2019.
/s/ Peter Garcia, by power of attorney
2021-03-24